

Solvency II

A look at the current proposals and impact on health insurance

16 May 2008

Clayton Balkind, KPMG

Solvency II - Agenda

- Background to Solvency II
- Issues arising from QIS3
- QIS4 developments
- Internal Models
- Modelling results a numerical example
- Key messages



Background to Solvency II

Objectives of Solvency II


Consultation Paper 7 sets out the following objectives for Solvency II:

The new system should:

- Assess overall solvency
- Be based on a three pillar structure, adapted to insurance
- Be built on a more risk sensitive approach, with incentives for proper risk management
- Increase harmonisation of quantitative and qualitative supervisory methods
- See more efficient and effective supervision of insurance groups and financial conglomerates
- Employs Lamfalussy or comitology techniques to adopt / adapt legislation efficiently
- Ensure consistency between financial sectors
- Be developed in parallel with international developments, and in particular be compatible with the estimated outcome of the international accounting standards board (IASB) work.



Solvency II regulatory timeline



Solvency II – Three-Pillar Approach

Three-pillar approach recommended in KPMG study for EU (and reflecting Basel II approach)

Pillar 1:

Quantitative capital requirements

- Technical provisions
- Minimum capital requirement (MCR)
- Solvency Capital Requirement (SCR)
- Investment rules

Market-consistent valuation
Validation of internal models

Pillar 2:

Qualitative supervisory review

- Principles for internal control and risk management
- Individual risk and capital assessment
- Supervisory review process

Market discipline

Pillar 3:

- Transparency
- Disclosure
- Support of risk-based supervision through market mechanisms

New focus for supervisors

Maximum level of harmonisation

'Use test'


More pressure from capital markets

More pressure from rating


agencies

The Actuarial Profession
making financial sense of the future

The Building Blocks



Technical Provisions – Market Consistent





Risk Margin – the Cost of Capital Approach

(1) Project the SCR for nonhedgeable risks


(2) Risk margin= Σ (CoC factor) x SCR_i x v

CoC= 6%





SCR: The Standard Formula





Issues arising from QIS3

Key findings:

- Good levels of UK involvement
- Generally lower reported solvency ratios
- Difficulties with MCR
- Difficulties with SCR
- Confusion over the calculation of the risk margin



QIS4 developments

Developments in QIS4

- The MCR calculation and design
- Review of stress tests applied
- Developments of health care module
- Investigating the impact on insurance groups' balance sheets
- Comparability and calibration of the standard formulae and internal models


Minimum Capital Requirement

- MCR < SCR
- 2 approaches tested in QIS 3:
 - Modular approach underwriting risk + market risk @ 90% VaR
 - Compact approach percentage of the SCR
- QIS 4 testing new 'linear approach' based on percentage of technical provisions and capital at risk.

QIS 4 tests for the life risk modules: SCR_{life}

| SCR _{life} | | | | | | | |
|---------------------|---------------------------------|--|---|---|--|---|------------------------------|
| Risk | Mortality | Longevity | Disability | Lapse | Expense | Catastrophe | Revision |
| Calculation | 10% increase in mortality rates | 25% decrease in mortality rates | 35% increase in disability rates for next year; 25% in subsequent years | The maximum of a permanent 50% fall, a permanent 50% increase or 30% of the surrender strain. | Higher by 10%. Inflation higher by 1%. Loadings can recover expenses (up to 75%) from year 2 | Mortality and disability up 1.5‰ over 1 year | 3% increase in annuity |

The healthcare capital module






Internal Models

ICAS to Solvency II - Considerations

Solvency II overview - The potential impact of Solvency II



Internal Models

- Article 110 of the Framework Directive allows companies to calculate their SCR using an internal model "as approved by the supervisory authorities."
- This can be a full or partial model.
- However the FSA has indicated it does not believe any existing ICAs are good enough to be used as internal models.

Reasons for Developing an Internal Model

- The standardised approach will most likely be calibrated conservatively suggesting that internal models will produce lower capital requirements.
- The improved risk modelling and additional insights provided by internal models should give those firms which use them a competitive advantage.
- An internal model should be an important part of a company's Enterprise Risk Management (ERM) framework.

Model Validation

- The Framework Directive sets out the high level principles for model validation:
 - Use test (article 117)
 - Statistical quality standards (article 118)
 - Calibration standards (article 119)
 - Profit and loss attribution (article 120)
 - Validation standards (article 121)
 - Documentation standards (article 122)

Key Requirements of Internal Models:

- Model widely used
- Plays important role in risk management and decision-making
- Sound actuarial and statistical techniques
- Data accurate, complete and appropriate
- Reflective of the business and covers all material risks
- Analysis of causes and sources of profits and losses
- Demonstrate how the categorisation of risk explains the causes
- Regular cycle of model validation
- Documentation
- No reliance on external model providers

Validation Principles

The Committee of European Banking Supervisors (CEBS) published the GL10 which set out the six principles to be applied to model validation in the context of credit risk models and Basel II. It is expected that a similar framework will be developed under Solvency II for insurance and other risks.

| Principle 1 | Validation is fundamentally about assessing the predictive ability of an institution's risk estimates. |
|-------------|--|
| Principle 2 | The institutions itself has primary responsibility for validation. |
| Principle 3 | Validation is an iterative process. |
| Principle 4 | There is no single validation method. |
| Principle 5 | Validation should encompass both quantitative and qualitative elements. |
| Principle 6 | Validation processes and outcomes should be subject to independent review. |

Embedding Internal Models:

- Used in pricing no proxies
- Used in setting economic capital
- Staff understanding
- Board understanding/training
- Formal, detailed reconciliation of results
- External review of model and processes
- Documentation
- Processes in place to keep models up to date

"State of Play" of current models

| CURRENT MODELS | SOLVENCY II MODELS |
|--|---|
| Different models used for Pricing, Pillar 1, Pillar 2, Economic Capital, Management Information In different business units | One model (or at least models that are consistent) used throughout the business to run the company! |
| Predefined risk measures for some risks | Ability to look at various risk measures and levels of confidence |
| Only key factors affecting risk modelled | Detailed granular assessment of risk |
| Analysis of Surplus on key lines Large unexplained items not uncommon | Review causes of profit and loss for each major business unit and demonstrate how categorisation of risk explains causes of profit and loss |
| Documentation of key processes of model | Documentation of model covering theory, design, operational, compliance and shortcomings of model |
| Reliance on external providers, e.g. ESGs, stochastic models | No black boxes |

A Practical Compromise?



- Improvements are required
 - Same model used in pricing, determining and allocating capital
 - More granular assessment of risk
 - All material risks captured
 - Model kept up to date in all areas
 - Better governance and documentation
- Benefits should outweigh costs!


Requirements of Internal Models:


- Internal model does not need to be a fully stochastic model
- Should cover all risks to which a capital value can be assigned
- Complex models may be run infrequently, updating parts of it more frequently where necessary
- Detailed disclosure requirements for each parameter within the model
 - Distribution, variability
 - Underlying data, calibration
 - Appropriateness and fit of model

Requirements of Internal Models (2):

- Alignment of pricing and capital models but not granularity
- Emphasis on proportionality
- Back-testing
 - Rework using historic experience and compare to actual
 - Level of granularity explains results?
 - Assess whether historic experience within agreed tolerance levels
 - Trends

UK Firms readiness for Internal Models





Modelling Results – a numerical example

Our Approach

 We constructed four portfolios each consisting of one of the following products: accelerated and standalone critical illness; income protection and private medical expense insurance.

| Accelerated CI | Standalone CI | Income protection | Private medical |
|--|--|---|---|
| A portfolio of 25, 25-year term assurances with CI cover sold 1 year apart to lives aged 35 | A portfolio of 25, 25-year CI only policies sold 1 year apart to lives aged 35 | A portfolio of 30 Income protection policies sold 1 year apart to lives aged 35 | A portfolio of 1-year polices sold to individuals and through company schemes |
| Sum assured: £250,000 | Sum assured: £250,000 | Income provided: 65% of £65,000 | |
| Annual Premium: £1176 | Annual Premium: £1150 | Annual Premium: £160 | |

Our Assumptions

| Assumption | Accelerated CI | Standalone CI | Income Protection |
|--------------------------|---|--|---|
| Valuation interest rates | Best estimate: - Risk free rates Prudent: - 5.07% pa before year 12, 4.03% after | Best estimate: - Risk free rates Prudent: - 5.07% pa before year 12, 4.03% after | Best estimate: - Risk free rates Prudent: - 4.03% pa |
| Mortality | Best estimate: - 54% of blended TMN00 / TSF00 table Prudent: - 96% of blended TMN00 / TSF00 table | Best estimate: - 93% of blended CIBT93 table Prudent: - 116% of blended CIBT93 table | No mortality assumptions |
| Morbidity | Best estimate: - 54% of blended CIBT93 table Prudent: - 96% of blended CIBT93 table | Best estimate: - 64% of blended CIBT93 table Prudent: - 80% of blended CIBT93 table | Best estimate: - 30% (inception) and 42% (termination) of blended CMIR12 table Prudent: - 48% (inception) and 33% (termination) of blended CMIR12 table |
| Expenses | Best estimate: - £20 per policy Prudent: - £30 per policy | Best estimate: - £20 per policy Prudent: - £30 per policy | Best estimate: - £20 per policy Prudent: - £30 per policy |
| Inflation | 4% (expense) | 4% (expense) | 4% (expense and benefit) |
| Commission | 5% | 5% | 5% |
| Lapses | Best estimate: - 11% p.a. Prudent: - 13% up to year 12 and 9% after | Best estimate: - 11% p.a. Prudent: - 13% up to year 12 and 9% after | Best estimate: - 11% p.a. Prudent: - 5.5% |
| Asset allocation | Gilts:Corporates: Equities:Cash 40:40:10:10 | Gilts:Corporates: Equities:Cash 40:40:10:10 | Gilts:Corporates: Equities:Cash 40:40:10:10 |

• For private medical expenses insurance we assumed a steady portfolio, no reinsurance and backing assets of cash and short term bonds.

Pillar 1 results

| £ amount | Accelerated CI | Standalone CI | Income protection | Private medical expense insurance |
|------------------------|----------------|---------------|----------------------|---|
| Case reserves and IBNR | | | | 21,434 |
| Outstanding claims | | | | 232 |
| UPR | | | | 88,744 |
| Mathematical reserves | 146,273 | 86,692 | 548,563 | 110,410 |
| Claims amount | | | | 34,969 |
| LTICR | 24,162 | 21,958 | 21,943 | |
| RCR | 3,557 | 2,189 | 16,762 | |
| Total | 173,992 | 110,839 | 587,268 | 145,379 |

ICA calculation: stress tests

| Category | Shock | |
|---------------|--------------------------------------|-------------|
| Interest Rate | Interest rates up | 1.70% |
| | Interest rates down | -1.43% |
| Lapses | Percentage decrease | 45% |
| Mortality | Mortality rate up | 20% |
| | Catastrophe shock | 4 per mille |
| Morbidity | Morbidity rate up | 35% |
| Longevity | Mortality rate down | 21% |
| Expenses | Renewal expenses (non- commission) | 17.75% |
| | Renewal expenses annual inflation up | 2.41% |
| Assets | Equity fall | -41% |
| | Interest rate up | 1.70% |
| | Interest rate down | -1.43% |
| | "A" rated credit spread widening | 1.20% |

ICA calculation: correlation

| | Insurance | Market | Credit | Operational |
|-------------|-----------|--------|--------|-------------|
| Insurance | 1 | 0.17 | 0.24 | 0.31 |
| Market | 0.17 | 1 | 0.62 | 0.25 |
| Credit | 0.24 | 0.62 | 1 | 0.25 |
| Operational | 0.31 | 0.25 | 0.25 | 1 |

ICA calculation: Accelerated critical illness

| Total Liability Breakdown | £ amount |
|---------------------------|----------|
| Best estimate liability | 68,424 |
| ICA | 77,636 |
| Total Liability | 146,060 |

| ICA Breakdown | £ amount |
|--------------------------------|----------|
| Equity Risk | 2,190 |
| Interest rate risk | 1,440 |
| MR Diversification benefit | -855 |
| Market Risk | 3,496 |
| Credit Risk | 1,804 |
| Mortality and catastrophe risk | 27,786 |
| Morbidity risk | 45,829 |
| Lapse risk | 34,181 |
| Expense risk | 870 |
| IR Diversification benefit | -35,542 |
| Insurance Risk | 73,124 |
| Operational risk | 8,539 |
| Undiversified capital | 86,962 |
| Diversification benefit | -9,326 |
| ICA | 77,636 |

ICA calculation: Standalone critical illness

| Total Liability Breakdown | £ amount |
|---------------------------|----------|
| Best estimate liability | 32,157 |
| ICA | 62,347 |
| Total Liability | 94,504 |

| ICA Breakdown | £ amount |
|--------------------------------|----------|
| Equity Risk | 1,368 |
| Interest rate risk | 808 |
| MR Diversification benefit | -454 |
| Market Risk | 1,722 |
| Credit Risk | 1,033 |
| Mortality and catastrophe risk | 0 |
| Morbidity risk | 54,853 |
| Lapse risk | 22,006 |
| Expense risk | 871 |
| IR Diversification benefit | -18,472 |
| Insurance Risk | 59,258 |
| Operational risk | 6,836 |
| Undiversified capital | 68,850 |
| Diversification benefit | -6,503 |
| ICA | 62,347 |

ICA calculation: Income protection

| Total Liability Breakdown | £ amount |
|---------------------------|----------|
| Best estimate liability | 148,824 |
| ICA | 127,754 |
| Total Liability | 276,578 |

| ICA Breakdown | £ amount |
|----------------------------|----------|
| Equity Risk | 6,330 |
| Interest rate risk | 5,203 |
| MR Diversification benefit | -2,571 |
| Market Risk | 8,962 |
| Credit Risk | 3,532 |
| "Longevity" risk | 62,796 |
| Morbidity risk | 56,708 |
| Lapse risk | 57,975 |
| Expense risk | 1,681 |
| IR Diversification benefit | -60,018 |
| Insurance Risk | 119,142 |
| Operational risk | 14,009 |
| Undiversified capital | 145,646 |
| Diversification benefit | -17,892 |
| ICA | 127,754 |

ICA calculation: Private medical

| Total Liability Breakdown | £ amount |
|---------------------------|----------|
| Best estimate liability | 110,410 |
| ICA | 36,553 |
| Total Liability | 146,963 |

| ICA Breakdown | £ amount |
|-------------------------|----------|
| Market Risk | 4,591 |
| Insurance Risk | 34,979 |
| Operational risk | 3,323 |
| Undiversified capital | 42,893 |
| Diversification benefit | -6,340 |
| ICA | 36,553 |

QIS 4 calculation: stress tests

| Category | SCR Shock | |
|---------------|--|-------------------------------|
| Interest Rate | Interest rates up | Prescribed |
| | Interest rates down | Prescribed |
| Lapses | Percentage change | Max (50% fall or 50% rise) |
| Mortality | Mortality rate up | 10% |
| | Catastrophe shock | 0.15% up over 1 year |
| Morbidity | Morbidity rate up -1 year - all subsequent years | 35% 25% |
| | Catastrophe shock | 0.15% up over 1 year |
| Longevity | Mortality rate down | 25% |
| Expenses | Renewal expenses (non-commission) | 10% |
| | Renewal expenses annual inflation up | 1% |
| Assets | Equity fall | -32% |
| | Interest rate up | Prescribed |
| | Interest rate down | Prescribed |
| | "A" rated spread | 1.03% of Sum(MV*dur) |

| Category | ICA Shock | |
|---------------|---------------------------------------|-------------|
| Interest Rate | Interest rates up | 1.70% |
| | Interest rates down | -1.43% |
| Lapses | Percentage decrease | 45% |
| | | |
| Mortality | Mortality rate up | 20% |
| | Catastrophe shock | 4 per mille |
| Morbidity | Morbidity rate up | 35% |
| Longevity | Mortality rate down | 21% |
| Expenses | Renewal expenses (non- commission) | |
| | Renewal expenses annual inflation up | 2.41% |
| Assets | Equity fall | -41% |
| | Interest rate up | 1.70% |
| | Interest rate down | -1.43% |
| | "A" rated credit spread widening | 1.20% |

QIS 4 calculation: correlation

SCR

| | Insurance | Market | Credit |
|-----------|-----------|--------|--------|
| Insurance | 1 | | |
| Market | 0.25 | 1 | |
| Credit | 0.25 | 0.25 | 1 |

ICA


| | Insurance | Market | Credit | Operational |
|-------------|-----------|--------|--------|-------------|
| Insurance | 1 | | | |
| Market | 0.17 | 1 | | |
| Credit | 0.24 | 0.62 | 1 | |
| Operational | 0.31 | 0.25 | 0.25 | 1 |

QIS 4 calculation: Critical illness


| Accelerated CI | £ amount |
|----------------------------------|----------|
| | |
| Best estimate liability | 68,424 |
| Risk margin | 19,237 |
| MCR | 11,943 |
| SCR | 59,714 |
| Total = BEL + RM + max(MCR, SCR) | 147,375 |

| Standalone CI | £ amount |
|----------------------------------|----------|
| | |
| Best estimate liability | 32,157 |
| Risk margin | 16,868 |
| MCR | 10,281 |
| SCR | 51,403 |
| Total = BEL + RM + max(MCR, SCR) | 100,429 |

QIS 4 calculation: Accelerated CI results



QIS 4 calculation: Standalone CI results




QIS 4 calculation: The SCR calculation – Accelerated CI

| Item | £ amount |
|-------------------------|----------|
| Equity | 2,262 |
| Interest rate | 1,778 |
| Spread | 1,602 |
| MR Diversification | -1,889 |
| Market Risk | 3,753 |
| Mortality | 6,344 |
| Morbidity | 35,076 |
| Lapse | 39,237 |
| Expense | 417 |
| Catastrophe | 16,543 |
| IR Diversification | -39,835 |
| Insurance Risk | 57,782 |
| Pre diversification | 61,535 |
| Diversification benefit | -2,703 |
| BSCR | 58,832 |
| Operational Risk | 882 |
| SCR | 59,714 |

| Item | £ amount |
|--------------------------------|----------|
| Equity Risk | 2,190 |
| Interest rate risk | 1,440 |
| MR Diversification benefit | -855 |
| Market Risk | 3,496 |
| Credit Risk | 1,804 |
| Mortality and catastrophe risk | 27,786 |
| Morbidity risk | 45,829 |
| Lapse risk | 34,181 |
| Expense risk | 870 |
| IR Diversification benefit | -35,542 |
| Insurance Risk | 73,124 |
| Operational risk | 8,539 |
| Undiversified capital | 86,962 |
| Diversification benefit | -9,326 |
| ICA | 77,636 |

QIS 4 calculation: The SCR calculation – Accelerated CI




QIS 4 calculation: The SCR calculation – Standalone CI

| Item | £ amount |
|-------------------------|----------|
| Equity | 1,063 |
| Interest rate | 970 |
| Spread | 917 |
| MR Diversification | -989 |
| Market Risk | 1,961 |
| Mortality | 0 |
| Morbidity | 41,996 |
| Lapse | 25,321 |
| Expense | 417 |
| Catastrophe | 8,272 |
| IR Diversification | -25,991 |
| Insurance Risk | 50,015 |
| Pre diversification | 51,976 |
| Diversification benefit | -1,435 |
| BSCR | 50,541 |
| Operational Risk | 863 |
| SCR | 51,403 |

| Item | £ amount |
|--------------------------------|----------|
| Equity Risk | 1,368 |
| Interest rate risk | 808 |
| MR Diversification benefit | -454 |
| Market Risk | 1,722 |
| Credit Risk | 1,033 |
| Mortality and catastrophe risk | 0 |
| Morbidity risk | 54,853 |
| Lapse risk | 22,006 |
| Expense risk | 871 |
| IR Diversification benefit | -18,472 |
| Insurance Risk | 59,258 |
| Operational risk | 6,836 |
| Undiversified capital | 68,850 |
| Diversification benefit | -6,503 |
| ICA | 62,347 |

QIS 4 calculation: The SCR calculation – Standalone CI




QIS 4 calculation: Income protection results

| Main QIS4 proposals | £ amount |
|----------------------------------|----------|
| | |
| Best estimate liability | 148,824 |
| Risk margin | 40,309 |
| MCR | 25,237 |
| SCR | 126,185 |
| Total = BEL + RM + max(MCR, SCR) | 315,318 |

| Alternative UK scenario | £ amount |
|----------------------------------|----------|
| | |
| Best estimate liability | 148,824 |
| Risk margin | 58,963 |
| MCR | 36,917 |
| SCR | 184,583 |
| Total = BEL + RM + max(MCR, SCR) | 392,370 |

QIS 4 calculation: Income protection results




QIS 4 calculation: The SCR calculation – Income protection

| Item | £ amount |
|-------------------------|----------|
| Equity | 4,920 |
| Interest rate | 6,068 |
| Spread | 3,138 |
| MR Diversification | -4,740 |
| Market Risk | 9,386 |
| Longevity | 76,897 |
| Morbidity | 43,216 |
| Lapse | 66,515 |
| Expense | 765 |
| Catastrophe | 6,963 |
| IR Diversification | 71,293 |
| Insurance Risk | 123,063 |
| Pre diversification | 132,449 |
| Diversification benefit | -6,710 |
| BSCR | 125,739 |
| Operational Risk | 446 |
| SCR | 126,185 |

| Item | £ amount |
|----------------------------|----------|
| Equity Risk | 6,330 |
| Interest rate risk | 5,203 |
| MR Diversification benefit | -2,571 |
| Market Risk | 8,962 |
| Credit Risk | 3,532 |
| "Longevity" risk | 62,796 |
| Morbidity risk | 56,708 |
| Lapse risk | 57,975 |
| Expense risk | 1,681 |
| IR Diversification benefit | -60,018 |
| Insurance Risk | 119,142 |
| Operational risk | 14,009 |
| Undiversified capital | 145,646 |
| Diversification benefit | -17,892 |
| ICA | 127,754 |


QIS 4 calculation: The SCR calculation – Income protection



QIS 4 calculation: Private medical results

| Break down of liability | £ amount |
|----------------------------------|----------|
| | |
| Best estimate liability | 108,796 |
| Risk margin | 320 |
| MCR | 7,100 |
| SCR | 27,785 |
| Total = BEL + RM + max(MCR, SCR) | 136,901 |

QIS 4 calculation: Private medical results




QIS 4 calculation: The SCR calculation – Private medical

| Item | £ amount |
|--------------------------|----------|
| Market Risk | 1,034 |
| Premium and reserve risk | 16,090 |
| Catastrophe | 17,749 |
| IR Diversification | 9,883 |
| Insurance Risk | 23,956 |
| Pre diversification | 24,990 |
| Diversification benefit | 754 |
| BSCR | 24,236 |
| Operational Risk | 3,549 |
| SCR | 27,785 |

| Item | £ amount |
|-------------------------|----------|
| Market Risk | 4,591 |
| Insurance Risk | 34,979 |
| Operational risk | 3,323 |
| Undiversified capital | 42,893 |
| Diversification benefit | 6,340 |
| ICA | 36,553 |

QIS 4 calculation: The SCR calculation – Private medical





Solvency II – Key Messages

Solvency II – Key messages

- The QIS process is the best way to influence the Solvency II proposals
- The current proposals have significant implications for some types of contracts
- High validation standards are expected for internal models
- Data and embedding requirements => long lead-time for use of internal models

Presenter's contact details

Clayton Balkind KPMG LLP (UK)

clayton.balkind@kpmg.co.uk www.kpmg.co.uk